Immutep IMMP 深 滬
等待開盤 08-10 09:30:00 美东时间
0.3858
+0.011
+2.85%
華盛通- 最 高0.3965
- 今 開0.386
- 成交量 6.64万股
- 最 低 0.3774
- 昨 收 0.3751
- 總市值 5.69万
- 52周最高 3.5299
- 市盈率 靜 --
- 換手率 0.05%
- 52周最低 0.2928
- 委 比 -58.07%
- 總股本 0.00亿
- 歷史最高 7.95
- 量 比 0.36
- 振 幅 5.09%
- 歷史最低 0.2928
- 每 手 1
- 風險率 0.98%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Immutep Quarterly Activities Report Q4 FY26
Immutep Limited provided an update on its activities for Q4 FY26, highlighting progress in its eftilagimod alfa (efti) program and IMP761 development. Pooled analysis of five efti trials showed a 7.7-month median overall survival benefit in biological responders across four tumor types. IMP761, the only LAG-3 agonist antibody in clinical development, met its primary safety endpoint and demonstrated significant pharmacodynamic activity in a first-...
07-30 12:00
Immutep balances TACTI-004 setback with upbeat efti and IMP761 data
Immutep Ltd ( ($AU:IMM) ) has issued an announcement. Immutep’s latest quarterl...
07-30 06:55
Immutep’s Sarcoma Quality-of-Life Data Accepted for ESMO 2026
Immutep Ltd ( ($AU:IMM) ) has shared an update. Immutep has had an abstract acc...
07-24 07:18
Immutep Wins Fourth U.S. Patent for Key Cancer Immunotherapy Combination
An update from Immutep Ltd ( ($AU:IMM) ) is now available. Immutep Limited has ...
07-14 10:22
Immutep Announces Positive Update For Phase I Trial Evaluation Of Eftilagimod Alfa
Key Results from INSIGHT-003 – Data Cutoff – 27 March 2026 Approximately 92% of patients enrolled in INSIGHT-003 had no or low PD-L1 expression (Tumour Proportion Score: TPS <50%), representing a population with significant unmet medical need. With a minimum of 30 months of follow-up, median Overall...
07-13 20:05
Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004
Immutep announced positive results from the INSIGHT-003 trial, showing eftilagimod alfa (efti) combined with KEYTRUDA and chemotherapy achieved a median overall survival (mOS) of 30.9 months in 1L non-squamous NSCLC patients, including those with low PD-L1 expression (TPS <50%). These outcomes surpass historical benchmarks. However, the TACTI-004 Phase III trial was discontinued due to lower objective response rates in the efti arm compared to pl...
07-13 12:00
摩根大通集团不再担任Immutep的主要股东
伊美特普有限公司（澳交所代码：IMM）发布公告，摩根大通公司及其关联方告知该公司，自2026年6月26日起不再是其主要股东。本次变动源于摩根大通旗下多家实体开展...
07-01 07:34
关键癌症试验因无效终止，Immutep股价暴跌83%后面临集体诉讼
生物技术公司Immutep Limited（NASDAQ： IMMP）正面临证券欺诈集体诉讼。此前该公司宣布，其针对一线非小细胞肺癌的关键三期临床试验TA...
06-11 03:24
Regal Partners Exits as Substantial Shareholder in Immutep
Immutep Ltd ( ($AU:IMM) ) has shared an announcement. Immutep Ltd has disclosed...
06-09 16:09
Immutep To Present Interim Phase I Data For IMP761 At EULAR 2026
First-in-human Phase I study met its primary endpoint, demonstrating favourable safety and tolerability in healthy volunteers in the single ascending dose part of the studyPhase I data demonstrate statistically
06-04 20:05
